Search This Blog

Monday, August 5, 2019

Revance Therapeutics EPS beats by $0.04

Revance Therapeutics (NASDAQ:RVNC): Q2 GAAP EPS of -$0.86 beats by $0.04.
Cash and equivalents of $90.03M
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)